Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High – Should You Buy?

Takeda Pharmaceutical Company Limited (NYSE:TAK) hit a new 52-week high on Monday . The company traded as high as $15.22 and last traded at $15.20, with a volume of 561724 shares trading hands. The stock had previously closed at $15.01.

Takeda Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The stock has a 50 day simple moving average of $13.83 and a two-hundred day simple moving average of $13.91. The company has a market cap of $48.25 billion, a PE ratio of 37.91, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. First Trust Advisors LP increased its holdings in shares of Takeda Pharmaceutical by 2.0% in the fourth quarter. First Trust Advisors LP now owns 3,240,932 shares of the company’s stock valued at $42,910,000 after purchasing an additional 62,718 shares during the period. FMR LLC increased its holdings in shares of Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after purchasing an additional 286,052 shares during the period. Van ECK Associates Corp increased its holdings in shares of Takeda Pharmaceutical by 1.6% in the fourth quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock valued at $29,266,000 after purchasing an additional 35,192 shares during the period. Northern Trust Corp increased its holdings in shares of Takeda Pharmaceutical by 14.6% in the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company’s stock valued at $24,806,000 after purchasing an additional 238,161 shares during the period. Finally, Managed Asset Portfolios LLC increased its holdings in shares of Takeda Pharmaceutical by 0.3% in the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock valued at $23,001,000 after purchasing an additional 4,069 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.